Byron Amin
Analyst
Piper Sandler
Equibles does not estimate personal net worth.
About Byron Amin
Byron Amin is recorded as Analyst at Piper Sandler. Byron Amin has spoken on 4 earnings calls and 1 other investor event across 5 companies, most recently for Opus Genetics, Inc. on September 9, 2026. Those appearances were for Opus Genetics, Inc. (IRD), Viking Therapeutics, Inc. (VKTX), Context Therapeutics Inc. (CNTX), ASCENTAGE and LENZ Therapeutics, Inc. (LENZ). The companies whose calls Byron Amin spoke on are classified in the Healthcare sector.
Byron Amin on recent calls
“Maybe for cohort two, can you talk about, you know, with the higher dose, are you doing anything that's different compared to the lower dose in terms of blood placement or the number of bloods?”
“For the maintenance trial, the 15 and the 17.5 milligram dose cohorts in the first 21 weeks, How should we think about the placebo-adjusted weight loss compared to the 15 milligram cohort in the Phase II trial where you reported a 13.1% placebo-adjusted weight loss?”
“So, you know, you enroll some pretty late-line patients in the ovarian cancer cohort and still reporting an encouraging response rate.”
“Maybe to start, for olorobatinib, what is your market share in China versus Iskiminib and Ponatinib, and which CML patients are you seeing the most adoptions? And then I guess, you know, for second half 2025, sales grew by about 7% versus first half 25.”
“For Q1, can you maybe tell us what the split is between the one-month pack and the three-month pack? My second question is I think previously you had estimated five refills per year.”
Affiliation history
-
Piper Sandler
Analyst
Transcript header (unverified)
Current
Company network
ASCENTAGE
Biotechnology · Healthcare
1 appearance
Latest appearance 2026-03-26
Recent activity
-
-
-
-
Earnings call
亚盛医药2025年年度业绩发布会
ASCENTAGE
-